
VIGL
Healthcare · Biotechnology · $375.7M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2025
EPS trend, 90 days to now · +0.7% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | Time not confirmed | -0.44 | 0.00 | +100.0% |
| Aug 5, 2025 | Time not confirmed | -0.43 | -0.56 | -29.8% |
| May 7, 2025 | Time not confirmed | -0.53 | -0.49 | +7.5% |
| Mar 13, 2025 | Time not confirmed | -0.54 | -0.57 | -5.6% |
| Nov 7, 2024 | Time not confirmed | -0.54 | -0.47 | +13.7% |
| Aug 13, 2024 | Time not confirmed | -0.55 | -0.52 | +5.5% |
| May 7, 2024 | Time not confirmed | -0.50 | -0.50 | 0.0% |
| Mar 26, 2024 | Before the open | -0.53 | -0.57 | -7.5% |
| Nov 7, 2023 | Before the open | -0.57 | -0.53 | +7.0% |
| Aug 8, 2023 | Before the open | -0.54 | -0.52 | +3.7% |
| May 10, 2023 | Before the open | -0.53 | -0.51 | +3.8% |
| Mar 21, 2023 | Before the open | -0.58 | -0.48 | +17.2% |
| Nov 10, 2022 | Before the open | -0.60 |
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a…
| -0.53 |
| +11.7% |
| Aug 8, 2022 | Before the open | -0.67 | -0.60 | +10.4% |
| May 12, 2022 | Before the open | -0.58 | -0.58 | 0.0% |
| Jan 10, 2022 | Before the open | -0.78 | -8.28 | -957.1% |
| Oct 8, 2021 | Time not confirmed | -0.50 | -0.15 | +70.0% |